Thursday - March 5, 2026
ViiV Healthcare Presents Pipeline Data for Two Investigational HIV Treatment Therapies With Potential for Twice-Yearly Dosing
February 26, 2026
LONDON, England, Feb. 26 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:

* * *

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing

- VH184, the first, third generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals

- Additional in-vitro data on VH184 demonstrate improved potency . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products